IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity
MassBiologics; Department of Biochemistry and Molecular Pharmacology; Schiffer Lab
Amino Acids, Peptides, and Proteins | Biochemistry | Immunity | Immunology of Infectious Disease | Immunoprophylaxis and Therapy | Immunotherapy | Infectious Disease | Microbiology | Virus Diseases
COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity or as a therapeutic has yet been developed to SARS-CoV-2. In this study we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks hACE2 receptor binding, by completely overlapping the hACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in human epithelial cells expressing hACE2. SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.
microbiology, biochemistry, SARS-CoV-2, mucosal immunity, antibody, COVID-19
Rights and Permissions
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
DOI of Published Version
Ejemel M, Li Q, Hou S, Schiller ZA, Wallace AL, Amcheslavsky A, Yilmaz NK, Toomey JR, Schneider R, Close BJ, Chen DY, Conway HL, Mohsan S, Cavacini LA, Klempner MS, Schiffer CA, Wang Y. IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity. bioRxiv [Preprint]. 2020 May 15:2020.05.15.096719. doi: 10.1101/2020.05.15.096719. PMID: 32511396; PMCID: PMC7263543. Link to article on publisher's site
bioRxiv : the preprint server for biology
Monir E, Li Q, Hou S, Schiller Z, Wallace A, Amcheslavsky A, Yilmaz NK, Toomey JR, Schneider R, Cavacini L, Klempner MS, Schiffer CA, Wang Y. (2020). IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity. University of Massachusetts Medical School Faculty Publications. https://doi.org/10.1101/2020.05.15.096719. Retrieved from https://escholarship.umassmed.edu/faculty_pubs/1718